Pfizer has picked up fresh bragging rights for its big RSV vaccine drive.
The pharma giant today spotlighted its second breakthrough drug designation for PF-06928316, or RSVpreF, for people 60 and over. That lands just a few weeks after their first BTD came through for infants.
The latest regulatory win has the potential for keeping the ball rolling at the FDA as Pfizer pushes ahead with its pivotal Phase III study in the older age bracket, which launched last fall. It also illustrates the stark difference in fortunes for this program compared to the rival GSK effort, as well as the collaboration between Sanofi and AstraZeneca for nirsevimab, which unexpectedly was tagged with mixed Phase III results recently.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 136,800+ biopharma pros reading Endpoints daily — and it’s free.